The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors

Asciminib is an allosteric high-affinity tyrosine kinase inhibitor (TKI) of the BCR-ABL1 protein kinase. This kinase is translated from the Philadelphia chromosome in chronic myeloid leukemia (CML). Marketing authorization for asciminib was granted on August 25, 2022 by the European Commission. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesileanu, C Mircea S, Michaleas, Sotirios, Gonzalo Ruiz, Rocio, Mariz, Segundo, Fabriek, Babs O, van Hennik, Paula B, Dedorath, Jutta, Dekic, Bruna, Unkrig, Christoph, Brandt, Andreas, Koenig, Janet, Enzmann, Harald, Delgado, Julio, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Regulatory Issues
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322123/
https://www.ncbi.nlm.nih.gov/pubmed/37141403
http://dx.doi.org/10.1093/oncolo/oyad119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322123/
https://www.ncbi.nlm.nih.gov/pubmed/37141403
http://dx.doi.org/10.1093/oncolo/oyad119

Ejemplares similares